Inhibiting the activity of specific uncontrolled myofibroblasts (uncontrolled/abnormal wound healing
The myofibroblast is responsible for supporting and maintaining a pro-fibrotic micro-environment. Our technology uniquely targets a range of fibrotic mediators mitigating their ability to activate normal fibroblast to become myofibroblast. Regulating key mediators, addresses the myofibroblast, slowing or halting fibrosis and enabling tissue regeneration.
The fibroblast is a mobile, critical cell type paramount in the construction, degradation, and reconstruction of the ECM (extracellular matrix). When activated in disease, the fibroblast transitions to an activated cell known as a myofibroblast. The myofibroblast can be part of normal wound healing, but when it persists , or expresses certain genes markers it produces an abnormal ECM, abnormal adhesion to the ECM, and an improper immune response, all driving disease progression in fibro-inflammatory disease (FID). This occurs in both fibrosis and cancer.
BLR Bio has developed a group of therapeutic biomolecules that are based on a natural occurring set of related proteins (called the CCN family) that together modulate and balance the conversion of normal fibroblasts to myofibroblasts in normal wound healing. With chronic injury the CCNs often fail to properly regulate and balance the creation and removal of myofibroblasts and inflammation, resulting in fibrosis and/or the facilitation of cancer growth and spread.
BLR’s novel biomolecule therapeutics target specific pro-inflammatory and pro-fibrotic elements, including the pro-fibrotic CCN proteins, thus re-creating a normal physiological balance and blocking/reversing to progression of fibrosis (or solid tumor cancers) and return the body to a disease-free homeostatic state.
Abnormal wound healing is key to the development of both fibro-inflammatory diseases and cancers. BLR drugs are based on a naturally occurring protein important in homeostasis and therefore are expected to be highly safe.
Current chemotherapeutic and immunotherapeutic (I/O)- based drugs are characteristically limited in solid tumor treatment due to side-effects, induced chemoresistance, and/or an inability to reach all tumor cells. This results in a limited patient susceptibility and less than optimal outcome for many. BLR drugs are designed to have low sides effects, high penetration, and capable of reducing chemoresistance to other chemo and I/O drugs when used in combination thus greatly increasing efficacy.
